1. Home
  2. KTTA

as of 12-12-2025 4:00pm EST

$1.13
+$0.01
+0.89%
Stocks Health Care Biotechnology: Pharmaceutical Preparations Nasdaq

Pasithea Therapeutics Corp is a biotechnology company. It is focused on the discovery, research, and development of treatments for central nervous system (CNS) disorders and other diseases, including RASopathies and certain cancers. It leveraging in the fields of neuroscience, translational medicine, and drug development. Its pipeline includes Neurofibromatosis Type 1, Amyotrophic Lateral Sclerosis (ALS), Multiple Sclerosis (MS), and Schizophrenia. Companies pipelines includes PAS-004 (Macrocyclic Small Module[MEK1/2]), PAS-003 (Monoclonal antibody),PAS-001 (Small Module).

Chart Type:
Time Range:
Founded: 2020 Country:
United States
United States
Employees: N/A City: MIAMI BEACH
Market Cap: 5.3M IPO Year: 2021
Target Price: $3.00 AVG Volume (30 days): 21.6M
Analyst Decision: Strong Buy Number of Analysts: 1
Dividend Yield:
N/A
Dividend Payout Frequency: N/A
EPS: -3.25 EPS Growth: N/A
52 Week Low/High: $0.28 - $3.85 Next Earning Date: 11-13-2025
Revenue: N/A Revenue Growth: N/A
Revenue Growth (this year): N/A Revenue Growth (next year): N/A

AI-Powered KTTA Daily Prediction

Machine learning model trained on 25+ technical indicators

Updated 3 days ago

AI Recommendation

hold
Model Accuracy: 76.55%
76.55%
Confidence

Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.

Latest Pasithea Therapeutics Corp. News

KTTA Breaking Stock News: Dive into KTTA Ticker-Specific Updates for Smart Investing

All KTTA News

Share on Social Networks: